review Open AccessTop 1% cited

Virus-like particles as a highly efficient vaccine platform: Diversity of targets and production systems and advances in clinical development

Vaccine · 2012 · Vol. 31(1) · pp. 58–83

Natasha Kushnir✉(Fraunhofer USA Center for Molecular Biotechnology)Stephen J. Streatfield(Fraunhofer USA Center for Molecular Biotechnology)Vidadi Yusibov(Fraunhofer USA Center for Molecular Biotechnology)

View via DOI Publisher page

Viral gastroenteritis research and epidemiology Animal Virus Infections Studies Transgenic Plants and ApplicationsImmunogenicityVirologyVirus-like particleBiologyHeterologousRecombinant DNAVirusViral envelopeComputational biologyAntigen

MeSH terms

HumansViral VaccinesVirosomesVaccines, Virus-Like Particle

Citations

579

FWCI

17.81

field-weighted impact

References

422

Percentile

100%

vs. same field & year

Citations per year

Cited by

Nanoparticle vaccines

Vaccine · 2013 · 904 citations

References

Expression, self-assembly, and antigenicity of the Norwalk virus capsid protein

Journal of Virology · 1992 · 853 citations

High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up

British Journal of Cancer · 2006 · 808 citations

Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial

The Lancet Oncology · 2005 · 1,577 citations

Citation Network

How this paper connects to the literature. Drag to explore, click any node to open that paper.